SBRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sabra Health Care REIT Inc (SBRA) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators suggest a bearish trend, and the stock lacks strong positive catalysts or proprietary trading signals. While the company has shown revenue growth, the recent analyst ratings and price target adjustments reflect concerns about near-term volatility and sector underperformance. Given the investor's profile, waiting for clearer positive signals or a more favorable entry point is advisable.
The technical indicators for SBRA are bearish. The MACD histogram is negative (-0.0407) and contracting, the RSI is neutral at 33.958, and the moving averages (SMA_200 > SMA_20 > SMA_5) indicate a downward trend. The stock is trading below the pivot level of 18.432, with support at 17.817 and resistance at 19.047.
Sabra Health Care REIT has shown a 10.2% revenue growth rate in FY 2025, and its debt-to-equity ratio of 0.9x is relatively better compared to some peers. The company has a diverse portfolio of 361 properties.
Analysts have expressed concerns about near-term volatility due to pending renegotiations of loans and potential asset sales. Rising interest rates could also increase debt costs. Recent analyst ratings reflect a cautious outlook, with some firms lowering price targets and issuing underperform ratings.
Sabra Health Care REIT generated $774.6 million in revenue for FY 2025, reflecting a 10.2% growth rate. Its debt-to-equity ratio is 0.9x, and its current ratio is 0.6x, indicating moderate financial stability.
Recent analyst ratings are mixed to negative. Scotiabank lowered its price target to $19 from $22, citing less attractive REIT valuations. Raymond James resumed coverage with an Underperform rating, highlighting potential near-term volatility. UBS and Cantor Fitzgerald raised their price targets to $22 but maintained Neutral ratings, while Wells Fargo remains constructive with an Overweight rating and a $22 price target.
